Avalo Therapeutics
Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
* | $185m | Private Placement VC | |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (75 %) | (4 %) | (1 %) | (19 %) | 234 % | (89 %) | (77 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (147 %) | (257 %) | (376 %) | (1493 %) | (207 %) | (1212 %) | (9231 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (570 %) | (238 %) | (948 %) | (1563 %) | (231 %) | (1640 %) | (7966 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 82 % | 174 % | 481 % | 1108 % | 173 % | 716 % | 5541 % |
Source: Company filings or news article
Related Content
Avalo Therapeutics is a clinical-stage biotechnology company specializing in the treatment of immune dysregulation. The company focuses on developing therapies that target the LIGHT signaling network, which plays a crucial role in autoimmune and inflammatory reactions in barrier organs. Avalo's pipeline emphasizes high-value potential first-in-class biologics aimed at moderating immune dysregulation in both acute and chronic inflammatory disorders.
Avalo Therapeutics operates in the biotechnology sector, primarily serving patients suffering from immune-related diseases. The company's business model revolves around the research, development, and eventual commercialization of its therapeutic candidates. Revenue generation is anticipated through the successful development and approval of these therapies, followed by their commercialization either independently or through strategic partnerships.
Avalo's market includes healthcare providers, research institutions, and potentially pharmaceutical companies interested in licensing or co-developing its therapies. The company aims to address unmet medical needs in the field of immunology, offering innovative solutions that could significantly improve patient outcomes.
Keywords: biotechnology, immune dysregulation, LIGHT signaling, autoimmune, inflammatory disorders, biologics, clinical-stage, therapies, immunology, healthcare.